Lumida
/MAZE
⌘K
Maze Therapeutics Inc

Maze Therapeutics Inc

MAZE
$24.60USD↓-0.89%-0.22 today

MARKET CAP

1.4B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$24 – $26

52W RANGE

$20
$54

AI Summary

Stalk
TrimMedium

In Stage 4 decline, MAZE retains a medium-term bearish bias driven by recent Support Failure and Bearish Pivot Point patterns, with price trading below declining EMAs. Price now rests at a multi-touch support zone, making short-term timing unclear. Selling into resistance around the 9- and 20-day EMAs on a failed bounce is preferred over immediate execution.

  • ↑36% mean UACR reduction in Horizon Trial exceeds 30% threshold
  • ↑MZE829 targets ~6 million US AMKD patients lacking approved therapy
  • ↓Q2 2026 EPS of –$0.76 missed the –$0.70 estimate, underscoring losses
Full analysis →
Sales, Adj.
No data
Gross Profit, Adj.
No data
EBITDA, Adj.
EBIT
Net Income